Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis

Journal of Cellular Biochemistry

Volumn 110, Issue 1, 2010, Pages 219-228

  Zhang, Lijun ^a   Peng, Xia ^a   Zhang, Zhanqin ^a   Feng, Yanling ^a   Jia, Xiaofang ^a   Shi, Yuxin ^a   Yang, Hua ^a   Zhang, Zhiyong ^a   Zhang, Xiaonan ^a   Liu, Liwen ^a   Yin, Lin ^a   Yuan, Zhenghong ^a,b  

^a SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

ANXA2; Liver fibrosis; Plasma membrane; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CELL MEMBRANE PROTEIN; LIPOCORTIN 2; PROTEOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBROGENESIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; UPREGULATION;

ANIMALS; ANNEXIN A2; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL MEMBRANE; COMPUTATIONAL BIOLOGY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; HEPATITIS B VIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; PROTEIN TRANSPORT; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SUBCELLULAR FRACTIONS;

HEPATITIS B VIRUS; RATTUS; SUIDAE;

EID: 77951699602     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22529     Document Type: Article

References (42)

1. Asamoto H, Ichibangase T, Uchikura K, Imai K. 2008. Application of an improved proteomics method, fluorogenic derivatization-liquid chromatography-tandem mass spectrometry, to differential analysis of proteins in small regions of mouse brain. J Chromatogr A 1208:147-155.
2. Baba Y, Uetsuka K, Nakayama H, Dot K. 2004. Rat strain differences in the early stage of porcine-serum-induced hepatic fibrosis. Exp Toxicol Pathol 55:325-330. (Pubitemid 38419706)
3. Baba Y, Saeki K, Onodera T, Doi K. 2005. Serological and immunohistochemical studies on porcine-serum-induced hepatic fibrosis in rats. Exp Mol Pathol 79:229-235. (Pubitemid 41566239)
4. Benyon RC, Iredale JP. 2000. Is liver fibrosis reversible? Gut 46:443-446.
5. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, Falcone DJ, Hajjar KA. 2004. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: Enhanced expression by macrophages. Blood 103:317-324. (Pubitemid 38029955)
6. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. 2008. Proteomics in liver fibrosis is more than meets the eye. Eur J Gastroenterol Hepatol 20:450-464. (Pubitemid 351533883)
7. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathology. Springer Semin Immunopathol 17:261-281.
8. de Laurentiis A, Donovan L, Arcaro A. 2007. Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J 1:12-32.
9. de Seigneux S, Malte H, Dimke H, Frokiaer J, Nielsen S, Frische S. 2007. Renal compensation to chronic hypoxic hypercapnia: Downregulation of pendrin and adaptation of the proximal tubule. Am J Physiol Renal Physiol 292: F1256-F1266. (Pubitemid 46572445)
10. Fujisawa G, Muto S, Okada K, Kusano E, Ishibashi S. 2006. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res 148:149-156. (Pubitemid 44287632)
11. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. 2007. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 53:1792-1799. (Pubitemid 47509672)
12. Gressner OA, Weiskirchen R, Gressner AM. 2007. Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 381:107-113. (Pubitemid 46719142)
13. Grigorescu M. 2006. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 15:149-159. (Pubitemid 44011767)
14. Gui SY, Wei W, Wang H, Wu L, Sun WY, Chen WB, Wu CY. 2006. Effects and mechanisms of crude astragalosides fraction on liver fibrosis in rats. J Ethnopharmacol 103:154-159. (Pubitemid 41796911)
15. Gveric D, Herrera BM, Cuzner ML. 2005. tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Am J Pathol 166:1143-1151. (Pubitemid 40524438)
16. Kaito M, Ishida S, Tanaka H, Horiike S, Fujita N, Adachi Y, Kohara M, Konishi M, Watanabe S. 2006. Morphology of hepatitis C and hepatitis B virus particles as detected by immunogold electron microscopy. Med Mol Morphol 39:63-71. (Pubitemid 44576785)
17. Liaw YF. 2009. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 29(Suppl. 1):100-107.
18. Liu Y, He J, Ji S, Wang Q, Pu H, Jiang T, Meng L, Yang X, Ji J. 2008. Comparative studies of early liver dysfunction in senescence-accelerated mouse using mitochondrial proteomics approaches. Mol Cell Proteomics 7:1737-1747.
19. Mabit H, Dubanchet S, Capel F, Dauguet C, Petit MA. 1994. In vitro infection of human hepatoma cells (HepG2) with hepatitis B virus (HBV): Spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences. J Gen Virol 75(Pt 10):2681-2689.
20. Mannova P, Fang R, Wang H, Deng B, McIntosh MW, Hanash SM, Beretta L. 2006. Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics 5:2319-2325. (Pubitemid 46040636)
21. Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K, Miyoshi H, Deguchi A, Himoto T, Usuki H, Wakabayashi H, Izuishi K, Suzuki Y, Iwama H, Deguchi K, Uchida N, Sabet EA, Arafa UA, Hassan AT, El-Sayed AA, Masaki T. 2008. Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 33:1157-1163.
22. Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stuhler K. 2009. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 49:1257-1266.
23. Pedersen SK, Harry JL, Sebastian L, Baker J, Traini MD, McCarthy JT, Manoharan A, Wilkins MR, Gooley AA, Righetti PG, Packer NH, Williams KL, Herbert BR. 2003. Unseen proteome: Mining below the tip of the iceberg to find low abundance and membrane proteins. J Proteome Res 2:303-311. (Pubitemid 37099100)
24. Pizarro-Cerda J, Cossart P. 2006. Bacterial adhesion and entry into host cells. Cell 124:715-727. (Pubitemid 43261447)
25. Pungpapong S, Kim WR, Poterucha JJ. 2007. Natural history of hepatitis B virus infection: An update for clinicians. Mayo Clin Proc 82:967-975. (Pubitemid 47206372)
26. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. 2001. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21:351-372.
27. Seth D, Leo MA, McGuinness PH, Lieber CS, Brennan Y, Williams R, Wang XM, McCaughan GW, Gorrell MD, Haber PS. 2003. Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol 163:2303-2317. (Pubitemid 37466474)
28. Seth D, Hogg PJ, Gorrell MD, McCaughan GW, Haber PS. 2008. Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. J Hepatol 48:614-627.
29. Smyth R, Lane CS, Ashiq R, Turton JA, Clarke CJ, Dare TO, York MJ, Griffiths W, Munday MR. 2009. Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol Toxicol.
30. Spano D, Cimmino F, Capasso M, D'Angelo F, Zambrano N, Terracciano L, Iolascon A. 2008. Changes of the hepatic proteome in hepatitis B-infected mouse model at early stages of fibrosis. J Proteome Res 7:2642-2653.
31. Strnad P, Lienau TC, Tao GZ, Lazzeroni LC, Stickel F, Schuppan D, Omary MB. 2006. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 43:1354-1363. (Pubitemid 43980115)
32. Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S. 2009. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 14:797-808.
33. Tsukamoto H, Matsuoka M, French SW. 1990. Experimental models of hepatic fibrosis: A review. Semin Liver Dis 10:56-65. (Pubitemid 20163706)
34. van Gijssel HE, Divi RL, Olivero OA, Roth MJ, Wang GQ, Dawsey SM, Albert PS, Qiao YL, Taylor PR, Dong ZW, Schrager JA, Kleiner DE, Poirier MC. 2002. Semiquantitation of polycyclic aromatic hydrocarbon-DNA adducts in human esophagus by immunohistochemistry and the automated cellular imaging system. Cancer Epidemiol Biomarkers Prev 11:1622-1629.
35. Villeneuve JP. 2005. The natural history of chronic hepatitis B virus infection. J Clin Virol 34(Suppl. 1):S139-S142. (Pubitemid 43197762)
36. Wang K, Fan X, Fan Y, Wang B, Han L, Hou Y. 2007. Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection. J Viral Hepat 14: 276-282. (Pubitemid 46452416)
37. Wynn TA. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524-529.
38. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW, Su IJ. 2009. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49:1962-1971.
39. Zhang L, Xie J, Wang X, Liu X, Tang X, Cao R, Hu W, Nie S, Fan C, Liang S. 2005. Proteomic analysis of mouse liver plasma membrane: Use of differential extraction to enrich hydrophobic membrane proteins. Proteomics 5:4510-4524. (Pubitemid 41739929)
40. Zhang L, Liu X, Zhang J, Cao R, Lin Y, Xie J, Chen P, Sun Y, Li D, Liang S. 2006a. Proteome analysis of combined effects of androgen and estrogen on the mouse mammary gland. Proteomics 6:487-497. (Pubitemid 43208028)
41. Zhang LJ, Wang XE, Peng X, Wei YJ, Cao R, Liu Z, Xiong JX, Yin XF, Ping C, Liang S. 2006b. Proteomic analysis of low-abundant integral plasma membrane proteins based on gels. Cell Mol Life Sci 63:1790-1804. (Pubitemid 44223087)
42. Zhang XN, Liu JX, Hu YW, Chen H, Yuan ZH. 2006c. Hyper-activated IRF-1 and STAT1 contribute to enhanced interferon stimulated gene (ISG) expression by interferon alpha and gamma co-treatment in human hepatoma cells. Biochim Biophys Acta 1759:417-425.